Antiretroviral News and Research

RSS

AIDS Healthcare Foundation rolls out new national ad campaign

As part of its ongoing advocacy efforts to spur President Obama and his administration to do more on AIDS, AIDS Healthcare Foundation is rolling out a new national ad campaign headlined 'What has the President done about AIDS?' The first leg of the campaign, a series of pointed online text and banner ads on Politico.com's Playbook and Pulse websites started running Monday July 4th on Mike Allen's Politico Playbook and will run through Friday July 15th on Politico's Pulse.

11 Jul 2011

U.N. report shows significant progress toward reaching MDGs, but mixed results in some areas

Significant progress is being made toward reaching the Millennium Development Goals (MDGs) by the 2015 deadline, but the poorest countries are not progressing as quickly and more must be done to improve health and development outcomes in those nations, according to this year's MDG report (.pdf), VOA News reports.

8 Jul 2011

Improved global safety monitoring of HIV drugs is needed

With at least five million people worldwide taking antiretroviral therapy for HIV infection, the International Forum for Collaborative HIV Research, in a PLoS Medicine Policy Forum published on Tuesday, "recommends that improved and sustained global drug safety monitoring, including monitoring for substandard products, drug diversion, inappropriate use, and toxicity, is critical," a press release from PLoS states.

7 Jul 2011

Simpler antibiotic combination could help prevent TB in patients with and without HIV

Johns Hopkins and South African scientists have further compelling evidence that new, simpler and shorter treatments with antibiotic drugs could dramatically help prevent tens of millions of people worldwide already infected with the bacterium responsible for tuberculosis, and especially those co-infected with HIV, from developing full-blown TB.

7 Jul 2011

India must not become complacent despite AIDS control program's success, Prime Minister says

"India's Prime Minister Manmohan Singh on Monday hailed the country's success in slashing new HIV/AIDS infections by half in the past decade, but warned against complacency," Agence France-Presse reports. Speaking at a conference on AIDS in New Delhi, Singh said the country's HIV prevention program "can justifiably claim a measure of success," but "there should be no room for complacency," as an estimated 2.4 million Indians are living with the disease, according to AFP.

6 Jul 2011

Infected astrocytes can cause neuroAIDS

A longstanding medical mystery - why so many people with HIV experience memory loss and other cognitive problems despite potent antiretroviral therapy - may have been solved by researchers at Albert Einstein College of Medicine of Yeshiva University.

2 Jul 2011

Study identifies key virus-sensing mechanism necessary for successful immune response against HIV

Although our body's defense mechanisms are usually capable of detecting and destroying many types of pathogens, some viruses are able to evade the immune system and make us sick. In particular, "retroviruses," such as human immunodeficiency virus (HIV), are notorious for eluding host immune defenses and causing disease.

1 Jul 2011

Multinational drug companies' scam

In an Al Jazeera opinion piece, the first in a two-part series, Khadija Sharife, a journalist and visiting scholar at the Center for Civil Society, examines how multinational drug companies control markets.

1 Jul 2011

Swaziland's supply of antiretroviral drugs running low

"Cash-strapped Swaziland's state hospitals have only two months' supplies of AIDS drugs, the country's health minister has told parliament in an assessment that AIDS patients and activists took as a death sentence," the Associated Press/Seattle Times reports. More than 60,000 Swazis receive antiretroviral medicine at no cost from state-run hospitals.

30 Jun 2011

Physicians urge FDA not to approve Truvada as an HIV prevention pill

Last week, a group of 55 U.S. physicians sent a letter to the U.S. Food & Drug Administration (FDA), urging the agency not to approve the use of Gilead's HIV/AIDS treatment drug Truvada for use as an HIV prevention pill - also known as "pre-exposure prophylaxis" (PrEP).

30 Jun 2011

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec Pharmaceuticals today announced that it has entered into a license agreement with Gilead Sciences, Inc., for the development and commercialization of a new once-daily single tablet fixed-dose antiretroviral combination product containing Tibotec's protease inhibitor PREZISTA® (darunavir) and Gilead's cobicistat, an investigational pharmacoenhancing or "boosting" agent.

28 Jun 2011

HIV drug linked to accelerated and early aging

New research published this Sunday reveals that a class of generic AIDS drugs often used to treat HIV in Africa and other poor regions can cause premature aging and lead to age-related illnesses such as heart disease and dementia.

27 Jun 2011

Some HIV drugs can cause premature ageing

A class of anti-retroviral drugs commonly used to treat HIV, particularly in Africa and low income countries, can cause premature ageing, according to research published today in the journal Nature Genetics. The study shows that the drugs damage DNA in the patient's mitochondria - the 'batteries' which power their cells.

27 Jun 2011

GeoVax opens third clinical trial site for testing HIV/AIDS vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a third site for testing the therapeutic potential of its HIV/AIDS vaccine.

24 Jun 2011

Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection

Tobira Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for HIV, announced today that it has initiated a Phase IIb clinical trial for the CCR5/CCR2 inhibitor cenicriviroc (TBR-652).

22 Jun 2011

DIA recognizes CAPRISA team for outstanding achievement in HIV prevention

Today the CAPRISA 004 study leadership team is being awarded the inaugural Drug Information Association (DIA) President's Award for Outstanding Achievement in World Health.

21 Jun 2011

Government and private sector must work together on HIV vaccine

The success of antiretroviral therapy for HIV/AIDS "has fooled us into believing HIV is under control. It is not. … The fact remains that no sexually acquired infection has ever been controlled in democratic societies except by vaccines," Lawrence Corey, president and director of the Fred Hutchinson Cancer Research Center and principal investigator of the international HIV Vaccine Trials Network, writes in a Wall Street Journal opinion piece.

21 Jun 2011

Public-private partnerships leading to successes in HIV treatment and prevention

The recent achievements in studies looking at treatment as prevention "were only made possible by the partnership between publicly funded scientists and private drug companies," Ward Cates, president of research at FHI; Salim Abdool Karim, director of the Centre for the AIDS Program of Research in South Africa; and Myron Cohen, director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease, write in an opinion piece in the Huffington Post.

21 Jun 2011

New clinical trial to evaluate safety of tenofovir gel in breastfeeding, pregnant women

Determining whether a promising HIV prevention gel is safe for women to use while they are pregnant or breastfeeding is the aim of a new clinical trial being conducted by the National Institutes of Health-funded Microbicide Trials Network.

21 Jun 2011

Local misconceptions of children's immune systems hindering HIV treatment in Malawi, study says

Some caregivers in rural Malawi have expressed a reluctance to begin antiretroviral therapy for children living with HIV because of a belief that their "bodies were too weak for pills and their blood was 'still raw,' but that as it 'ripened' with time, HIV-related opportunistic infections would leave them," according to a study presented this week at the 1st International HIV Social Science and Humanities Conference in Durban, South Africa, PlusNews reports.

15 Jun 2011

Antiretroviral News and Research

AIDS Healthcare Foundation rolls out new national ad campaign

U.N. report shows significant progress toward reaching MDGs, but mixed results in some areas

Improved global safety monitoring of HIV drugs is needed

Simpler antibiotic combination could help prevent TB in patients with and without HIV

India must not become complacent despite AIDS control program's success, Prime Minister says

Infected astrocytes can cause neuroAIDS

Study identifies key virus-sensing mechanism necessary for successful immune response against HIV

Multinational drug companies' scam

Swaziland's supply of antiretroviral drugs running low

Physicians urge FDA not to approve Truvada as an HIV prevention pill

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

HIV drug linked to accelerated and early aging

Some HIV drugs can cause premature ageing

GeoVax opens third clinical trial site for testing HIV/AIDS vaccine

Tobira commences cenicriviroc Phase IIb clinical trial for HIV infection

DIA recognizes CAPRISA team for outstanding achievement in HIV prevention

Government and private sector must work together on HIV vaccine

Public-private partnerships leading to successes in HIV treatment and prevention

New clinical trial to evaluate safety of tenofovir gel in breastfeeding, pregnant women

Local misconceptions of children's immune systems hindering HIV treatment in Malawi, study says

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News